For better or for worse, the COVID-19 pandemic has affected nearly every aspect of life as we know it. As the virus evolves, so do we—from individuals to health systems, the country, public health policies, and more.
African American nurse leaders in ONS have paved the way in eliminating cancer disparities, identifying and tackling social determinants of health, and providing Black communities with educational and clinical resources.
Biomarker testing is an essential tool when choosing the right treatment for many advanced solid cancers. However, tissue-based testing may take weeks to get results with a chance that not enough tissue was collected to complete the entire biomarker panel. Blood draw–based liquid biopsies may be a useful alternative to identify a tumor’s biomarker details and can be performed by testing for circulating tumor DNA (ctDNA).
Combining a CDK4/6 inhibitor and fulvestrant improves overall survival consistently among patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to a U.S. Food and Drug Administration (FDA) analysis. The agency reported the findings in Lancet Oncology.
Since the first checkpoint inhibitor was approved in 2011, we have made tremendous leaps in immunotherapy in a short span of 10 years. Now we see immunotherapy combined with a variety of options, including chemotherapy or other oral and IV targeted therapy.
Immunotherapy has revolutionized cancer treatment, especially for patients with diseases considered otherwise incurable. Since May 2017, the U.S. Food and Drug Administration (FDA) has approved 27 immunotherapy combinations, including chemoimmunotherapy and regimens with targeted therapies, and researchers are reporting highly promising data from clinical trials of its combination with radiation.
As cancer care delivery changes, oncology nurses step up to the challenge: they adapt and develop solutions to fuel the future of nursing education, certification, and practice. During the November 2021 ONS Hackathon™, launched in partnership with the Oncology Nursing Certification Corporation (ONCC), teams were tasked to identify methods that address issues in the delivery of cancer care and prepare the future nursing workforce to care for patients with cancer anywhere.
An estimated 16% of patients with cancer experience depressive spectrum disorders in oncologic, hematologic, and palliative care settings, seriously affecting their quality of life. Although conventional antidepressants can be effective in many situations, they are associated with adverse effects, such as fatigue, drowsiness, sleep difficulties, nausea, weight gain, nervousness, dry mouth, blurred vision and sexual dysfunction.
America must make a drastic change in its approach to addressing health disparities for it to ensure adequate healthcare delivery, according to the National Cancer Institute’s Continuing Umbrella of Research Experiences Distinguished Scholars October 2021 speaker Robert Winn, MD.
Unprecedented new funding will expand and diversify the country’s healthcare workforce, address workforce shortages, and support more than 22,700 healthcare providers committed to working in underserved communities, according to a statement from the White House. Vice President Kamala Harris announced the $1.5 billion investment into the National Health Service Corps, Nurse Corps, and Substance Use Disorder Treatment and Recovery programs in November 2021.